-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 11, 2022, Nimbus Therapeutics announced a collaboration agreement with Eli Lilly to jointly develop an AMPK activator developed by Nimbus for the treatment of metabolic diseases
.
Under the agreement, Lilly will pay up to $496 million in research and development expenses plus potential milestone payments, in addition to a percentage share
of sales.
AMPK activator is one of
Nimbus' core pipelines.
The AMPK signal path is shown in
the figure below.
AMPK, AMP-dependent protein kinase, is a key molecule in the regulation of energy metabolism and one of the core of
research on diabetes and other metabolism-related diseases.
AMPK is widely expressed in various metabolism-related organs, including fat, brain, muscle, heart, kidney, liver, etc
.
Academician Lin Shengcai is an expert in the study of AMPK pathway, and in February 2022, Lin Shengcai's team published an article in Nature and found that PEN2 is the target of metformin, and metformin activates the AMPK pathway
through PEN2.
In October this year, Lin Shengcai's team published a research article
on Aldometanib, a new AMPK activator.
summary
summary AMPK activator has great potential in the treatment of metabolic diseases such as diabetes, NAFLD, and obesity, and with the clarity of mechanism research, translational research has also entered an accelerated stage, and has attracted more and more attention
from multinational pharmaceutical companies.
Original link:
